Posts Tagged ‘psychotropic medications’

Death of 7-year old prompts Florida officials to ask FDA to forbid allowing foster kids as guinea pigs in drug trials

Monday, July 19th, 2010

Pharmalot
By Ed Silverman
July 19, 2010

Last year, a 7-year-old foster boy named Gabriel Myers committed suicide in Florida and, after reams of publicity and hand-wringing over the use of psychotropic medications in such children, a state task force recommended, among other things, that children never be allowed to participate in a clinical trial designed to evaluate new psychotropic meds or whether such drugs approved for adults should be given to children.

The move was prompted, in part, because a Florida psychiatrist, Sohail Punjwani, who treated the boy before he committed suicide, received an FDA warning letter for failing “to protect the rights, safety and welfare” of children enrolled in clinical trials (back story). Before the suicide, the psychiatrist prescribed to kids several drugs, some of which weren’t approved by the FDA for use on children and had been linked to dangerous side effects, including an increased risk of suicide among children (back story).

As part of the follow-up, George Sheldon, who head’s Florida’s Department of Children and Families, wrote FDA commish Margaret Hamburg for info about any foster children who might have participated in clinical trials for psychotropic meds (read the letter) and asked the FDA to forbid foster kids from participating in these trials. Last month, the agency wrote back to say the agency does not agree with a “blanket prohibition” on enrolling foster children. Why? Such a policy fails to account for the greater risk of off-label prescribing and research involving children can yield benefits that cannot be obtained by tracking usage in adults, Jill Warner, acting associate commissioner for the FDA’s Special Medical Programs, wrote back (see here). Drugmakers, by the way, also have something at stake – they receive an extra six months of marketing exclusivity in return for having conducted the pediatric trials.

We asked Florida officials if they are rethinking their position. The answer? No way. The state is resolute.

Read entire article:  http://www.pharmalot.com/2010/07/florida-tells-fda-no-children-in-psychotropic-trials/?utm_source=feedburner&utm_medium=email&utm_campaign=Feed%3A+Pharmalot+%28Pharmalot

« Return to news items


Share

Medscape – Psychotropic Medications Linked to Serious Adverse Drug Reactions in Children

Friday, July 2nd, 2010

Medscape
By Deborah Brauser
July 2, 2010

Psychotropic medications are associated with adverse drug reactions (ADRs), many of which are serious, in children younger than 17 years, according to a new database study from Danish researchers.

Results also showed that all but one of the psychotropic-related ADRs for children between the ages of birth and 2 years were serious, including birth defects such as neonatal withdrawal syndrome, ventricular septal defects, and premature labor.

These findings were “probably due to the mothers’ intake of psychotropic medicine, primarily antidepressants and antipsychotics, during pregnancy,” write the study authors.

For the overall patient population, the largest share of reported ADRs came from psychostimulants (42%), followed by antidepressants (31%) and antipsychotics (24.5%).

“The high number of serious ADRs reported for psychotropic medicines in the pediatric population should be a concern for health care professionals and physicians,” the study authors write.

In addition, “clinicians must be aware of the risks for the unborn child if they treat pregnant women with [these drugs],” coinvestigator Ebba Hansen, MSc, professor of social pharmacy and director for the FKL-Research Center for Quality in Medicine Use at the University of Copenhagen, Denmark, told Medscape Medical News.

She noted that many of the general practitioners interviewed for this study “thought that SSRI [selective serotonin reuptake inhibitor] antidepressants are harmless. Therefore, we recommend that treatment of pregnant women with psychotropic drugs should be an issue for specialists only.”

The study is published online in BMC Research Notes.

ADR Evidence Lacking

Although regulatory authorities have issued warnings about risks associated with the use of psychotropics in pediatric patients, “little evidence has been reported about the ADRs of these medicines in practice,” write the study authors.

“Overall, we have very little information about [ADRs] in children, and especially in infants, as vulnerable groups are excluded from the clinical trials that document a medication’s efficacy and safety before licensing and marketing,” said Professor Hansen.

For this study, her team evaluated 4500 ADRs in children listed in the national Danish ADR database between 1998 and 2007.

“Spontaneous ADR reporting [is] an important contributor to knowledge about safety of medicines,” the study authors write. They note that spontaneous reports are “the main source for information about new and previous unknown ADRs.”

Serious ADRs Found

Results showed that 429 of the ADRs reported during the study period were for psychotropic medications. Of these, 241 (56%) were deemed serious.

A total of 50% of the psychotropic ADRs reported were for adolescents between the ages of 11 and 17 years (n = 214), of which 45% were serious. Almost 19% were for children between the ages of birth and 2 years (n = 80).

In addition, 39% of the overall psychotropic-related ADRs were from the “nervous and psychiatric disorders” categories. When looking at sex, 59% of the total ADRs reported were for boys.

A total of 79 of the 80 ADRs associated with psychotropics in the children younger than 2 years were serious, and 2 of these were fatal (one was associated with citalopram due to chorioamnionitis and the other with fluoxetine due to persistent fetal circulation).

Finally, 40% of all psychotropic ADRs were associated with the psychostimulants methylphenidate and atomoxetine, whereas 59% of the ADRs reported for antipsychotics were associated with ziprasidone, olanzapine, and risperidone. A total of 61% of the total ADRs reported for antidepressants were with sertraline and citalopram.

Read entire article:  http://www.medscape.com/viewarticle/724547
(Free registration required for Medscape)

« Return to news items


Share

Antidepressant use in U.S. has almost doubled with 10% of people over 6 taking antidepressants

Monday, August 3rd, 2009

Amanda Gardner
HealthDay Reporter
August 3, 2009

Antidepressant use among U.S. residents almost doubled between 1996 and 2005, along with a concurrent rise in the use of other psychotropic medications, a new report shows.

The increase seemed to span virtually all demographic groups.

“Over 10 percent of people over the age of 6 were receiving anti-depression medication. That strikes me as significant,” said study author Dr. Mark Olfson, a professor of clinical psychiatry at Columbia University/New York State Psychiatric Institute in New York City.

According to background information in the study, antidepressants are now the most widely prescribed class of drugs in the United States. The expansion in use dates back to the 1980s, with the introduction of the antidepressant Prozac (fluoxetine).

The study found that 5.84 percent of U.S. residents aged 6 and over were using antidepressants in 1996, compared with 10.12 percent in 2005. That’s 13.3 million people, up to 27 million people.

“This is a 20-year trend and it’s very powerful,” remarked Dr. Eric Caine, chair of the department of psychiatry and co-director of the Center for the Study of Prevention of Suicide at the University of Rochester Medical Center.

This happened despite a “black box” warning mandated for many antidepressant medications by the U.S. Food and Drug Administration in 2004, the study authors noted.

Read entire article:  http://health.usnews.com/articles/health/healthday/2009/08/03/antidepressant-use-in-us-has-almost-doubled.html

Posted August 3, 2009

By Amanda Gardner
HealthDay Reporter

« Return to news items


Share